Takara Bio and Rubicon Genomics Announce Merger Agreement

Takara Bio USA Holdings, Inc. (“TBUSH”) and Rubicon Genomics, Inc. (“Rubicon”), have announced the signing of a merger agreement pursuant to which TBUSH will acquire Rubicon, a privately-owned company headquartered in Ann Arbor, Michigan. Rubicon is a leading provider of pre-analytical library preparation kits that increase the accuracy, efficiency and speed of genomic analysis. TBUSH is a wholly owned subsidiary of Takara Bio Inc. (“Takara Bio“), a leading global biotechnology and life science company headquartered in Shiga, Japan. Takara Bio USA, Inc. (“TBUSA”, formerly known as Clontech Laboratories, Inc.) is a wholly owned subsidiary of TBUSH, and both TBUSA and TBUSH are part of the global Takara Bio Group.

The Takara Bio Group provides a wide range of life science products and services under the Takara®, Clontech®, and Cellartis® brands that assist discovery, translational and clinical scientists in the advancement of their work. The Rubicon acquisition will allow the Takara Bio Group to augment and expand its worldwide commercial offerings in next generation sequencing (NGS) sample preparation and expand into new markets.

Highlights of the Merger:

  • Adds complementary products for NGS library preparation and genetic analysis to Takara Bio Group’s global reagent product mix
  • Expands Takara Bio Group’s product portfolio into IVF and other clinical markets
  • Strengthens Takara Bio Group’s leadership in low-input and single-cell pre-analytical sample preparation
  • Increases access of Rubicon’s technologies and products by leveraging Takara Bio Group’s research market expertise and global commercial reach

“This acquisition builds on Takara Bio Group’s commitment to develop a differentiated NGS portfolio and provide our customers with a broader offering of genetic analysis solutions, particularly in the area of library preparation,” said Carol Lou, President, TBUSA. “Rubicon’s technologies and products complement our current expertise and offerings such as our portfolio of cDNA synthesis, low-input and single cell RNA-seq products based on our proprietary SMART® technology.  We welcome Rubicon into the Takara Bio Group and are looking forward to strengthening and expanding our product offerings in the fields of genomics, sequencing, single-cell and clinical applications with their unique technologies.”

“Joining Takara Bio Group provides access to their global reach and research market expertise that will accelerate the adoption of our highly sensitive NGS library preparation and genetic analysis workflow solutions by more laboratories around the world,” said Rubicon CEO James Koziarz, Ph.D., “We are excited to have the opportunity to combine our proprietary suite of products with those of Takara Bio Group to provide more comprehensive solutions to researchers and clinical labs.”

Rubicon’s technology is also complementary with the WaferGen Bio-systems, Inc. instrument platforms and technologies which TBUSH announced earlier this year it is acquiring, and anticipates will close in March 2017. The combined acquisitions are synergistic and will allow Takara Bio Group to provide the exciting benefits of the combined portfolios to the life science community.

The transaction is subject to customary closing conditions.  Upon the effectiveness of the merger, TBUSH will own all outstanding capital stock of Rubicon for a purchase price of approximately 75 million dollars.

Source – PR Newswire

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.